Ruiz Ortiz M, Romo E, Mesa D et al. Am J Cardiol 2011;107:1489–93.
This study assessed the efficacy, under daily clinical practice conditions, of oral anticoagulation for patients aged ≥80 years with non-valvular atrial fibrillation. Patients were treated as per standard guidelines issued by scientific societies, and their progress monitored. All serious adverse events were logged according to patient group (oral anticoagulation vs. control). The findings suggest that oral anticoagulation is safe in this at-risk subgroup of older patients, and embolic event and mortality rates were lower than in controls.
The beneficial effect of antithrombotic treatment on mortality and morbidity in patients with atrial fibrillation (AF) is well established. However, the gain in terms of embolic episode prevention is frequently offset by hemorrhagic episodes. The aforementioned balance is of significant importance in subgroups of particularly frail patients, such as older individuals. Therefore, the aim of the present study was to evaluate the effectiveness and safety of oral anticoagulation as thromboembolic prophylaxis for patients aged ≥80 years with non-valvular AF in daily clinical practice.